FieldE. O., CauchiM. N., GibbsJ. E.: The transfer of refractoriness to GvH disease in F1 hybrid rats.Transplantation, 5: 241–247, 1967.
2.
FieldE. O., GibbsJ. E.: Reduced sensitivity of F-1 hybrid rats to re-challenge with parental strain spleen cells.Clin. Exp. Immun., 1: 195–205, 1966.
3.
GoldmanJ. M., AisenbergA. C.: Incidence of antibody to EB virus, herpes simplex, and cytomegalovirus in Hodgkin's disease.Cancer, 26: 327–331, 1970.
4.
HowardJ. G., WoodruffM. F. A.: Effect of the graft-versus-host reaction on the immunological responsiveness of the mouse.Proc. Roy Soc. B., 154: 532–539, 1961.
5.
JohanssonB., KleinG., HenleW., HenleG.: Epstein-Barr virus (EBV)-associated antibody patterns in malignant lymphoma and leukemia. I. Hodgkin's disease.Int. J. Cancer, 6: 450–462, 1970.
6.
KaplanH. S., SmithersD. W.: Auto-immunity in man and homologous disease in mice in relation to the malignant lymphomas.Lancet, 2: 1–4, 1959.
MöllerG.: Studies on the mechanism of immunological enhancement of tumor homografts. I. Specificity of immunological enhancement.J. Nat. Cancer Inst., 30: 1153–1175, 1963.
9.
OlinerH., SchwartzR., DameshekW.: Studies in experimental autoimmune disorders. I. Clinical and laboratory features of autoimmunization (runt disease) in the mouse.Blood, 17: 20–44, 1961.
10.
SchwartzR. S., Andre-SchwartzJ., ArmstrongM. Y. K., BeldottiL.: Neoplastic sequelae of allogenic disease. I. Theoretical considerations and experimental design.Ann. N. Y. Acad. Sci., 129: 804–821, 1966.
11.
SchwartzR. S., BeldottiL.: Malignant lymphomas following allogenic disease: transition from an immunological to a neoplastic disorder.Science, 149: 1511–1514, 1965.
12.
TylerA.: Clues to the etiology, pathology and therapy of cancer provided by analogies with transplantation disease.J. Nat. Cancer Inst., 25: 1197–1229, 1960.
